Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US90466Y1038
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01163JG34
UNCY

Unicycive Therapeutics, Inc.
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Unicycive Therapeutics, Inc.
ISIN
US90466Y1038
TICKER
UNCY
MIC
XNAS
REUTERS
UNCY.OQ
BLOOMBERG
UNCY US
Thu, 18.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are en...
Wed, 17.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) be...
Tue, 16.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFI...
Mon, 15.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are en...
Sat, 13.09.2025       Unicycive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi...
Sat, 13.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on beh...
Fri, 12.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFI...
Thu, 11.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) be...
Thu, 11.09.2025       Unicycive Therapeutics

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”). Unicycive is a clinical-stage biotechnology company. For more information, s...
Thu, 11.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are en...
Silent Ad
Tue, 09.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFIN...
Mon, 08.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on beha...
Mon, 08.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are enc...
Sat, 06.09.2025       Unicycive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Sat, 06.09.2025       Unicycive Therapeutics

SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and comme...
Fri, 05.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFIN...
Thu, 04.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are enc...
Wed, 03.09.2025       Unicycive Therapeutics

NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on beha...
Thu, 28.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are enc...
Wed, 27.08.2025       Unicycive Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Silent Ad
Wed, 27.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers.  The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on beha...
Tue, 26.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are enc...
Tue, 26.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFIN...
Fri, 22.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District of California, and docketed under 25-cv-06923, is on behal...
Fri, 22.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFIN...
Wed, 20.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY) and certain of its officers....
Mon, 18.08.2025       Unicycive Therapeutics

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commi...
Mon, 18.08.2025       Unicycive Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Mon, 18.08.2025       Unicycive Therapeutics

Ensures Intellectual Property Protection Until 2040 Ensures Intellectual Property Protection Until 2040...
Mon, 18.08.2025       Unicycive Therapeutics

SAN DIEGO, Aug. 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and comme...
Sat, 16.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Thu, 14.08.2025       Unicycive Therapeutics

- Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC)...
Mon, 11.08.2025       Unicycive Therapeutics

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Thu, 31.07.2025       Unicycive Therapeutics

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Sun, 27.07.2025       Unicycive Therapeutics

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Tue, 22.07.2025       Unicycive Therapeutics

NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Sat, 19.07.2025       Unicycive Therapeutics

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Thu, 17.07.2025       Unicycive Therapeutics

NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Sat, 12.07.2025       Unicycive Therapeutics

NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mon, 07.07.2025       Unicycive Therapeutics

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mon, 07.07.2025       Unicycive Therapeutics

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright...
Wed, 02.07.2025       Unicycive Therapeutics

NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Mon, 30.06.2025       Unicycive Therapeutics

--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC)...
Tue, 17.06.2025       Unicycive Therapeutics

Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025...
Tue, 10.06.2025       Unicycive Therapeutics

- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor...
Thu, 22.05.2025       Unicycive Therapeutics

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences....
Wed, 21.05.2025       Unicycive Therapeutics

LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The previously announc...
Wed, 14.05.2025       Unicycive Therapeutics

- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025...
Tue, 01.04.2025       Unicycive Therapeutics

LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7,...
Mon, 31.03.2025       Unicycive Therapeutics

      - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025...